Xealth Joins Epic App Orchard to Drive Digital Health Engagement

Platform Powers Digital Health Initiatives at Leading Health Systems

SEATTLE–(BUSINESS WIRE)–#AppOrchardXealth, the leading platform for scaling digital health, today announced that it has joined Epic’s App Orchard online marketplace. This integration enables health care organizations running on Epic to utilize the Xealth platform natively within the electronic health record (EHR), streamlining provider workflow and simplifying access to digital health assets.

As health care organizations turn to digital health tools to supplement care plans by delivering patient education, digital programs, and device monitoring, they require a way to simply and securely manage these programs from within the provider workflow. Having Xealth’s platform available via the App Orchard helps clinicians quickly incorporate this functionality, so they can prescribe and monitor digital health content, apps, devices and services to patients’ desktop and mobile devices. Xealth also delivers analytics to inform program success and allow for evaluation and optimization of digital health programs.

“Xealth drives engagement and utilization of digital health tools. By integrating digital solutions into the clinician workflow within the EHR, we make it easy for clinicians to both order and monitor engagement with the digital tools that can ultimately help deliver the best results,” said Mike McSherry, chief executive officer of Xealth. “With Xealth’s presence in the App Orchard, health care organizations will be able to easily launch new digital health programs and understand their impact faster and more completely than ever before.”

Xealth powers more than 30 digital health solutions, connecting patients with educational content, transportation, meal delivery, e-commerce product recommendations and other services needed to improve health outcomes. Monitoring and analytics capabilities assist health care organizations in determining which digital health strategies are working and how to optimize results. Originally incubated and launched at Providence St. Joseph Health in 2017, Xealth works with Atrium Health, Cleveland Clinic, Duke Health, UPMC and other leading health systems.

About Xealth

Xealth is a platform for digital health that enables health systems to easily organize, integrate, deploy and activate digital health tools for measurable clinical and financial results. Through the secure Xealth platform, clinicians can find and order the right digital health tools and programs for patients direct from the EHR workflow, send these digital health orders to the patient’s smartphone or computer, and then monitor patient engagement and analyze the effects of more engaged patients. Xealth spun out of Providence St. Joseph Health (PSJH) in 2017, and investors include McKesson Ventures, Novartis, Philips, and ResMed as well as Atrium Health, Cleveland Clinic, Memorial Care Innovation Fund, Providence Ventures, UPMC and the Froedtert and Medical College of Wisconsin Health Network.

For more information, visit www.xealth.com or follow us on LinkedIn or Twitter.

Epic is a registered trademark of Epic Systems Corporation. Any additional trademarks or servicemarks contained herein are the property of their respective owners.

Contacts

Cynthia Church, Xealth

Phone: 304 771 5755

Email: cynthia.church@xealth.com

Staff

Recent Posts

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health…

39 minutes ago

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- ChemLex, a next-generation AI-for-science company, today announced the establishment…

39 minutes ago

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

16 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

16 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

16 hours ago